Company type | Subsidiary (formerly: Public) |
---|---|
Nasdaq: CBST | |
Industry | Pharmaceuticals (Biopharmaceuticals & Biotherapeutics) |
Founded | 1992 |
Defunct | 2015 |
Headquarters | Lexington, Massachusetts |
Key people | Robert J. Perez, President, CEO; |
Products | Product Pipeline |
Revenue | $926.4 million USD (2012) |
Parent | Merck & Co. |
Website | www.cubist.com |
Cubist Pharmaceuticals was an American biopharmaceutical company that targeted pathogens like MRSA.
. [1] The company employed 638 people, mostly in Lexington, MA. [2] On 8 December 2014, Merck & Co. acquired Cubist for $102 per share in cash ($8.4 billion). [3]
Cubist was founded in May 1992 by John K. Clarke, Paul R. Schimmel, Ph.D. and Barry M. Bloom, Ph.D, all of whom were also directors. [4] Cubist appeared on Fortune 2010’s List of fastest growing companies, and was named to the 2010 Deloitte Technology Fast 500. [5]
In 2011, the company acquired Adolor, maker of a drug for treatment of constipation. [6]
The company expected sales of its drug Cubicin to grow to more than 1 billion dollars per year.
In July 2013, Cubist Pharmaceuticals agreed to purchase Trius Therapeutics and Optimer Pharmaceuticals for around $1.6 billion. [7]
In 2014, succeeding Michael Bonney as President, Robert J. Perez, was announced to take leadership on January 1, 2015. [8]
In January 2015 Cubist Pharmaceuticals became a wholly owned subsidiary of Merck & Co.
The company developed Cubicin ( daptomycin) for injection, the first antibiotic in a class of anti-infectives called lipopeptides. In 2011, Cubist settled a patent litigation with Teva Pharmaceutical Industries regarding Cubicin. [9] In April 2011 it reached a deal with Optimer Pharmaceuticals in which its class of bacterium fighting drugs will be co marketed with Optimer's Fidaxomicin/Dificid (for $15 million per year). [10]
In 2011, its product pipeline focused on gram-negative bacterial infections, [11] Clostridium difficile-associated diarrhea, [12] and respiratory syncytial virus. [13]
Tedizolid was approved by the US Food and Drug Administration on June 20, 2014. [14] [15]
{{
citation}}
: Unknown parameter |agency=
ignored (
help)